SP SAP Drug Development

Veterinary Development of Substance P-Saporin (SP-SAP)

A quick update on the pursuit of conditional approval of SP-SAP to  treat bone cancer pain in dogs. The FDA has already approved Minor Use/Minor Species (MUMS) designation for the drug, providing extended market exclusivity to treat the >10,000 annual cases of canine bone cancer-related pain, and the ability to commercialize the drug as soon …

Veterinary Development of Substance P-Saporin (SP-SAP) Read More »

Veterinary Development of Substance P-Saporin (SP-SAP)

A groundbreaking pain therapeutic is poised for conditional approval in 2015 to treat bone cancer pain in dogs. The FDA has already approved Minor Use/Minor Species (MUMS) designation for the drug, providing extended market exclusivity to treat the >10,000 annual cases of canine bone cancer-related pain, and the ability to commercialize the drug as soon …

Veterinary Development of Substance P-Saporin (SP-SAP) Read More »

Cancer Pain Relief in Pet Dogs has Direct Translation into Human Chronic Pain Conditions

Based on the recent publication by: Brown DC, Agnello K. (2013) Intrathecal substance p-saporin in the dog: efficacy in bone cancer pain. Anesthesiology 119(5):1178-1185 and the October 2013 press release by the American Society of Anesthesiologists, “Man’s best friends’ chronic pain relieved with new treatment, study finds: Findings could be useful to human cancer patients.” …

Cancer Pain Relief in Pet Dogs has Direct Translation into Human Chronic Pain Conditions Read More »

Cover Article: FDA Gives Green Light to Human Clinical Trials for Cancer Pain

Contributed by Douglas A. Lappi, Ph.D., President/Chief Scientific Officer, Advanced Targeting Systems, San Diego, CA Substance P-Saporin (SP-SAP), ATS’s patented conjugate being developed for cancer pain therapy, has attracted a considerable amount of attention recently. Back-to-back publications, a press release and editorial were featured in the November issue of the journal Anesthesiology. The first article, …

Cover Article: FDA Gives Green Light to Human Clinical Trials for Cancer Pain Read More »

$3 Million Award from National Cancer Institute

Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases and for research into the function of biological systems, has been awarded $3 million from the National Cancer Institute (NCI). Representatives from the NCI stated that the Advanced Targeting Systems proposal was ranked #1 …

$3 Million Award from National Cancer Institute Read More »

Chronic Pain Drug – Update on SP-SAP Development

ATS continues to make progress toward human clinical trials with SP-SAP. Thanks to the financial support of the National Institutes of Health, National Institute of Mental Health, preclinical studies have been completed, protocols for drug production have been written and the first of two toxicology studies is done. This first study is a GLP toxicology …

Chronic Pain Drug – Update on SP-SAP Development Read More »

Shopping Cart
Scroll to Top